M3814 (nedisertib) 8445 InChi: InChI=1S/C29H26N4O2/c1-3-30-29(34)25-16-15-24(18-31-25)27-20(2)32-28-26(10-7-17-33(27)28)35-19-21-11-13-23(14-12-21)22-8-5-4-6-9-22/h4-18H

InChi: InChI=1S/C29H26N4O2/c1-3-30-29(34)25-16-15-24(18-31-25)27-20(2)32-28-26(10-7-17-33(27)28)35-19-21-11-13-23(14-12-21)22-8-5-4-6-9-22/h4-18H

suppresses ribonucleotide reductase activity with an IC50 of 8

1H3/b10-4-

2 and 5 μM Neferine are used in the remaining experiments

003 μg/mL against O

M3814 (nedisertib) 8445 InChi: InChI=1S/C29H26N4O2/c1-3-30-29(34)25-16-15-24(18-31-25)27-20(2)32-28-26(10-7-17-33(27)28)35-19-21-11-13-23(14-12-21)22-8-5-4-6-9-22/h4-18HNedisertib (M3814) is a potent and selective inhibitor of DNA dependent Protein Kinase (DNA PK), with an IC50 of <3 nM. Nedisertib (Compound 136) is a potent and selective inhibitor of DNA PK, with an IC50 of <3 nM for DNA PK and <0. 5 for cellular pDNA PK. In combination with IR, Nedisertib shows efficacy in all of the 6 mouse models of human cancer. In all models, a dose of 2 Gy administered daily for 1 week in combination with Nedisertib induces